Longitudinal Trends in Serum Levels of Mycobacterial Secretory (30 kD) and Cytoplasmic (65 kD) Antigens During Chemotherapy of Pulmonary Tuberculosis Patients

Antigen 85 (mol. wt 30,000) (30 kD), secreted by actively growing mycobacteria under axenic conditions, and mol. wt 65,000 (65 kD), a cytoplasmic antigen released during mycobacterial lysis, were used to monitor the efficacy of chemotherapy in previously untreated pulmonary tuberculosis (UPTB) patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scandinavian journal of infectious diseases 1998, Vol.30 (4), p.363-369
Hauptverfasser: SETHNA, K. B, MISTRY, N. F, DHOLAKIA, Y, ANTIA, N. H, HARBOE, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 369
container_issue 4
container_start_page 363
container_title Scandinavian journal of infectious diseases
container_volume 30
creator SETHNA, K. B
MISTRY, N. F
DHOLAKIA, Y
ANTIA, N. H
HARBOE, M
description Antigen 85 (mol. wt 30,000) (30 kD), secreted by actively growing mycobacteria under axenic conditions, and mol. wt 65,000 (65 kD), a cytoplasmic antigen released during mycobacterial lysis, were used to monitor the efficacy of chemotherapy in previously untreated pulmonary tuberculosis (UPTB) patients using enzyme-linked immunosorbent assay. Sera from 125 UPTB patients were examined for each of the 2 antigens individually and for the ratio of secretory (30 kD) to cytoplasmic (65 kD) antigen (SCR), before commencement of treatment, after intensive phase (IP), completion of optimum period of treatment (COPT) and 6 months post-COPT. 116 controls (normals and contacts) were also checked for these antigens. The detection of 30 kD and 65 kD antigens in UPTB patients had a sensitivity ranging from 50-57% (mean 30 kD value: 0.64 +/- 1.24 ngs/ml) to 20-22% (mean 65 kD value: 0.51 +/- 1.87 ngs/ml), respectively, whereas in controls it ranged from 2-8% (0.05 +/- 0.28 ngs/ml) to 14-47% (0.09 +/- 0.22 ngs/ml), respectively. Although the decline in 30 kD positivity was more evident at COPT, computation of the SCR denoted efficacy of chemotherapy more readily at IP. Similarly, SCR resolved the ambiguity between individual antigen levels and the clinical status of a patient. Since significant numbers of patients demonstrated 30 kD at IP it may be computed that the lifespan of circulating 30 kD in serum could be at least 2 months after the start of treatment, declining gradually thereafter. Although seromonitoring for secretory antigen generally reflects the efficacy of chemotherapy, the interpretation of findings clearly requires further elucidation.
doi_str_mv 10.1080/00365549850160657
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_9817516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70053810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-d5f87e71b8eca3263d0ea4b9be6a0a3b70e5c18c1deb8dabd49229367d2e83203</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEKkvhA3BA8gGhclgYx5vEEVyqLf-kRVTqco4m9mTXxbEX26HKl-lnJcsulRBSTyPN-72nGb0se87hDQcJbwFEWRSLWhbASyiL6kE242XB57yW8DCb7fX5BMjH2ZMYrwFgUQo4yU5qyauCl7PsduXdxqRBG4eWrQM5HZlx7IrC0LMV_SIbme_Y11H5FlWiYCbuilSg5MPIzgSwHxevGTrNlmPyO4uxN4qdlcWf_blLZkMusoshGLdhyy31Pm0p4G7c514OtvcOp6T10FJQg_XRRHaJyZBL8Wn2qEMb6dlxnmbfP35YLz_PV98-fVmer-ZqISDNddHJiireSlIo8lJoIFy0dUslAoq2AioUl4praqXGVi_qPK9FWemcpMhBnGavDrm74H8OFFPTm6jIWnTkh9hUAIWQfA_yA6iCjzFQ1-yC6af7Gw7NvpPmv04mz4tj-ND2pO8cxxIm_eVRx6jQdgGdMvEOy6cXK7GPeX_AjOt86PHGB6ubhKP14a9H3HfFu3_sW0KbtgoDNdd-CFP98Z4ffgN2E7qO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70053810</pqid></control><display><type>article</type><title>Longitudinal Trends in Serum Levels of Mycobacterial Secretory (30 kD) and Cytoplasmic (65 kD) Antigens During Chemotherapy of Pulmonary Tuberculosis Patients</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Taylor &amp; Francis Journals Complete</source><creator>SETHNA, K. B ; MISTRY, N. F ; DHOLAKIA, Y ; ANTIA, N. H ; HARBOE, M</creator><creatorcontrib>SETHNA, K. B ; MISTRY, N. F ; DHOLAKIA, Y ; ANTIA, N. H ; HARBOE, M</creatorcontrib><description>Antigen 85 (mol. wt 30,000) (30 kD), secreted by actively growing mycobacteria under axenic conditions, and mol. wt 65,000 (65 kD), a cytoplasmic antigen released during mycobacterial lysis, were used to monitor the efficacy of chemotherapy in previously untreated pulmonary tuberculosis (UPTB) patients using enzyme-linked immunosorbent assay. Sera from 125 UPTB patients were examined for each of the 2 antigens individually and for the ratio of secretory (30 kD) to cytoplasmic (65 kD) antigen (SCR), before commencement of treatment, after intensive phase (IP), completion of optimum period of treatment (COPT) and 6 months post-COPT. 116 controls (normals and contacts) were also checked for these antigens. The detection of 30 kD and 65 kD antigens in UPTB patients had a sensitivity ranging from 50-57% (mean 30 kD value: 0.64 +/- 1.24 ngs/ml) to 20-22% (mean 65 kD value: 0.51 +/- 1.87 ngs/ml), respectively, whereas in controls it ranged from 2-8% (0.05 +/- 0.28 ngs/ml) to 14-47% (0.09 +/- 0.22 ngs/ml), respectively. Although the decline in 30 kD positivity was more evident at COPT, computation of the SCR denoted efficacy of chemotherapy more readily at IP. Similarly, SCR resolved the ambiguity between individual antigen levels and the clinical status of a patient. Since significant numbers of patients demonstrated 30 kD at IP it may be computed that the lifespan of circulating 30 kD in serum could be at least 2 months after the start of treatment, declining gradually thereafter. Although seromonitoring for secretory antigen generally reflects the efficacy of chemotherapy, the interpretation of findings clearly requires further elucidation.</description><identifier>ISSN: 0036-5548</identifier><identifier>EISSN: 1651-1980</identifier><identifier>DOI: 10.1080/00365549850160657</identifier><identifier>PMID: 9817516</identifier><identifier>CODEN: SJIDB7</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Antibodies, Bacterial - immunology ; Antigens, Bacterial - blood ; Antitubercular Agents - therapeutic use ; Bacterial diseases ; Bacterial diseases of the respiratory system ; Biological and medical sciences ; Drug Therapy, Combination ; Enzyme-Linked Immunosorbent Assay ; Ethambutol - therapeutic use ; Human bacterial diseases ; Humans ; Infectious diseases ; Isoniazid - therapeutic use ; Medical sciences ; Mycobacterium tuberculosis - immunology ; Pyrazinamide - therapeutic use ; Rifampin - therapeutic use ; Time Factors ; Treatment Outcome ; Tropical medicine ; Tuberculosis, Pulmonary - drug therapy ; Tuberculosis, Pulmonary - immunology</subject><ispartof>Scandinavian journal of infectious diseases, 1998, Vol.30 (4), p.363-369</ispartof><rights>1998 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1998</rights><rights>1998 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-d5f87e71b8eca3263d0ea4b9be6a0a3b70e5c18c1deb8dabd49229367d2e83203</citedby><cites>FETCH-LOGICAL-c430t-d5f87e71b8eca3263d0ea4b9be6a0a3b70e5c18c1deb8dabd49229367d2e83203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/00365549850160657$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/00365549850160657$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2430737$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9817516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SETHNA, K. B</creatorcontrib><creatorcontrib>MISTRY, N. F</creatorcontrib><creatorcontrib>DHOLAKIA, Y</creatorcontrib><creatorcontrib>ANTIA, N. H</creatorcontrib><creatorcontrib>HARBOE, M</creatorcontrib><title>Longitudinal Trends in Serum Levels of Mycobacterial Secretory (30 kD) and Cytoplasmic (65 kD) Antigens During Chemotherapy of Pulmonary Tuberculosis Patients</title><title>Scandinavian journal of infectious diseases</title><addtitle>Scand J Infect Dis</addtitle><description>Antigen 85 (mol. wt 30,000) (30 kD), secreted by actively growing mycobacteria under axenic conditions, and mol. wt 65,000 (65 kD), a cytoplasmic antigen released during mycobacterial lysis, were used to monitor the efficacy of chemotherapy in previously untreated pulmonary tuberculosis (UPTB) patients using enzyme-linked immunosorbent assay. Sera from 125 UPTB patients were examined for each of the 2 antigens individually and for the ratio of secretory (30 kD) to cytoplasmic (65 kD) antigen (SCR), before commencement of treatment, after intensive phase (IP), completion of optimum period of treatment (COPT) and 6 months post-COPT. 116 controls (normals and contacts) were also checked for these antigens. The detection of 30 kD and 65 kD antigens in UPTB patients had a sensitivity ranging from 50-57% (mean 30 kD value: 0.64 +/- 1.24 ngs/ml) to 20-22% (mean 65 kD value: 0.51 +/- 1.87 ngs/ml), respectively, whereas in controls it ranged from 2-8% (0.05 +/- 0.28 ngs/ml) to 14-47% (0.09 +/- 0.22 ngs/ml), respectively. Although the decline in 30 kD positivity was more evident at COPT, computation of the SCR denoted efficacy of chemotherapy more readily at IP. Similarly, SCR resolved the ambiguity between individual antigen levels and the clinical status of a patient. Since significant numbers of patients demonstrated 30 kD at IP it may be computed that the lifespan of circulating 30 kD in serum could be at least 2 months after the start of treatment, declining gradually thereafter. Although seromonitoring for secretory antigen generally reflects the efficacy of chemotherapy, the interpretation of findings clearly requires further elucidation.</description><subject>Antibodies, Bacterial - immunology</subject><subject>Antigens, Bacterial - blood</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the respiratory system</subject><subject>Biological and medical sciences</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Ethambutol - therapeutic use</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Isoniazid - therapeutic use</subject><subject>Medical sciences</subject><subject>Mycobacterium tuberculosis - immunology</subject><subject>Pyrazinamide - therapeutic use</subject><subject>Rifampin - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tropical medicine</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><subject>Tuberculosis, Pulmonary - immunology</subject><issn>0036-5548</issn><issn>1651-1980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxSMEKkvhA3BA8gGhclgYx5vEEVyqLf-kRVTqco4m9mTXxbEX26HKl-lnJcsulRBSTyPN-72nGb0se87hDQcJbwFEWRSLWhbASyiL6kE242XB57yW8DCb7fX5BMjH2ZMYrwFgUQo4yU5qyauCl7PsduXdxqRBG4eWrQM5HZlx7IrC0LMV_SIbme_Y11H5FlWiYCbuilSg5MPIzgSwHxevGTrNlmPyO4uxN4qdlcWf_blLZkMusoshGLdhyy31Pm0p4G7c514OtvcOp6T10FJQg_XRRHaJyZBL8Wn2qEMb6dlxnmbfP35YLz_PV98-fVmer-ZqISDNddHJiireSlIo8lJoIFy0dUslAoq2AioUl4praqXGVi_qPK9FWemcpMhBnGavDrm74H8OFFPTm6jIWnTkh9hUAIWQfA_yA6iCjzFQ1-yC6af7Gw7NvpPmv04mz4tj-ND2pO8cxxIm_eVRx6jQdgGdMvEOy6cXK7GPeX_AjOt86PHGB6ubhKP14a9H3HfFu3_sW0KbtgoDNdd-CFP98Z4ffgN2E7qO</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>SETHNA, K. B</creator><creator>MISTRY, N. F</creator><creator>DHOLAKIA, Y</creator><creator>ANTIA, N. H</creator><creator>HARBOE, M</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Longitudinal Trends in Serum Levels of Mycobacterial Secretory (30 kD) and Cytoplasmic (65 kD) Antigens During Chemotherapy of Pulmonary Tuberculosis Patients</title><author>SETHNA, K. B ; MISTRY, N. F ; DHOLAKIA, Y ; ANTIA, N. H ; HARBOE, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-d5f87e71b8eca3263d0ea4b9be6a0a3b70e5c18c1deb8dabd49229367d2e83203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Antibodies, Bacterial - immunology</topic><topic>Antigens, Bacterial - blood</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the respiratory system</topic><topic>Biological and medical sciences</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Ethambutol - therapeutic use</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Isoniazid - therapeutic use</topic><topic>Medical sciences</topic><topic>Mycobacterium tuberculosis - immunology</topic><topic>Pyrazinamide - therapeutic use</topic><topic>Rifampin - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tropical medicine</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><topic>Tuberculosis, Pulmonary - immunology</topic><toplevel>online_resources</toplevel><creatorcontrib>SETHNA, K. B</creatorcontrib><creatorcontrib>MISTRY, N. F</creatorcontrib><creatorcontrib>DHOLAKIA, Y</creatorcontrib><creatorcontrib>ANTIA, N. H</creatorcontrib><creatorcontrib>HARBOE, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SETHNA, K. B</au><au>MISTRY, N. F</au><au>DHOLAKIA, Y</au><au>ANTIA, N. H</au><au>HARBOE, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal Trends in Serum Levels of Mycobacterial Secretory (30 kD) and Cytoplasmic (65 kD) Antigens During Chemotherapy of Pulmonary Tuberculosis Patients</atitle><jtitle>Scandinavian journal of infectious diseases</jtitle><addtitle>Scand J Infect Dis</addtitle><date>1998</date><risdate>1998</risdate><volume>30</volume><issue>4</issue><spage>363</spage><epage>369</epage><pages>363-369</pages><issn>0036-5548</issn><eissn>1651-1980</eissn><coden>SJIDB7</coden><abstract>Antigen 85 (mol. wt 30,000) (30 kD), secreted by actively growing mycobacteria under axenic conditions, and mol. wt 65,000 (65 kD), a cytoplasmic antigen released during mycobacterial lysis, were used to monitor the efficacy of chemotherapy in previously untreated pulmonary tuberculosis (UPTB) patients using enzyme-linked immunosorbent assay. Sera from 125 UPTB patients were examined for each of the 2 antigens individually and for the ratio of secretory (30 kD) to cytoplasmic (65 kD) antigen (SCR), before commencement of treatment, after intensive phase (IP), completion of optimum period of treatment (COPT) and 6 months post-COPT. 116 controls (normals and contacts) were also checked for these antigens. The detection of 30 kD and 65 kD antigens in UPTB patients had a sensitivity ranging from 50-57% (mean 30 kD value: 0.64 +/- 1.24 ngs/ml) to 20-22% (mean 65 kD value: 0.51 +/- 1.87 ngs/ml), respectively, whereas in controls it ranged from 2-8% (0.05 +/- 0.28 ngs/ml) to 14-47% (0.09 +/- 0.22 ngs/ml), respectively. Although the decline in 30 kD positivity was more evident at COPT, computation of the SCR denoted efficacy of chemotherapy more readily at IP. Similarly, SCR resolved the ambiguity between individual antigen levels and the clinical status of a patient. Since significant numbers of patients demonstrated 30 kD at IP it may be computed that the lifespan of circulating 30 kD in serum could be at least 2 months after the start of treatment, declining gradually thereafter. Although seromonitoring for secretory antigen generally reflects the efficacy of chemotherapy, the interpretation of findings clearly requires further elucidation.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>9817516</pmid><doi>10.1080/00365549850160657</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0036-5548
ispartof Scandinavian journal of infectious diseases, 1998, Vol.30 (4), p.363-369
issn 0036-5548
1651-1980
language eng
recordid cdi_pubmed_primary_9817516
source MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete
subjects Antibodies, Bacterial - immunology
Antigens, Bacterial - blood
Antitubercular Agents - therapeutic use
Bacterial diseases
Bacterial diseases of the respiratory system
Biological and medical sciences
Drug Therapy, Combination
Enzyme-Linked Immunosorbent Assay
Ethambutol - therapeutic use
Human bacterial diseases
Humans
Infectious diseases
Isoniazid - therapeutic use
Medical sciences
Mycobacterium tuberculosis - immunology
Pyrazinamide - therapeutic use
Rifampin - therapeutic use
Time Factors
Treatment Outcome
Tropical medicine
Tuberculosis, Pulmonary - drug therapy
Tuberculosis, Pulmonary - immunology
title Longitudinal Trends in Serum Levels of Mycobacterial Secretory (30 kD) and Cytoplasmic (65 kD) Antigens During Chemotherapy of Pulmonary Tuberculosis Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T21%3A07%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20Trends%20in%20Serum%20Levels%20of%20Mycobacterial%20Secretory%20(30%20kD)%20and%20Cytoplasmic%20(65%20kD)%20Antigens%20During%20Chemotherapy%20of%20Pulmonary%20Tuberculosis%20Patients&rft.jtitle=Scandinavian%20journal%20of%20infectious%20diseases&rft.au=SETHNA,%20K.%20B&rft.date=1998&rft.volume=30&rft.issue=4&rft.spage=363&rft.epage=369&rft.pages=363-369&rft.issn=0036-5548&rft.eissn=1651-1980&rft.coden=SJIDB7&rft_id=info:doi/10.1080/00365549850160657&rft_dat=%3Cproquest_pubme%3E70053810%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70053810&rft_id=info:pmid/9817516&rfr_iscdi=true